Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies by HONG, JP et al.
Recombinant human epidermal growth factor treatment of
radiation-induced severe oral mucositis in patients with
head and neck malignanciesecc_971 636..641
J.P. HONG, md, phd, Departments of Plastic and Reconstructive Surgery, University of Ulsan College of Medicine,
Asan Medical Center, Seoul, S.-W. LEE, md, phd, Departments of Radiation Oncology, University of Ulsan College
of Medicine, Asan Medical Center, Seoul, S.Y. SONG, md, phd, Departments of Radiation Oncology, University of
Ulsan College of Medicine, Asan Medical Center, Seoul, S.D. AHN, md, phd, Departments of Radiation Oncology,
University of Ulsan College of Medicine, Asan Medical Center, Seoul, S.S. SHIN, md, phd, Departments of
Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, E.K. CHOI, md, phd,
Departments of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul,&
J.H. KIM, md, phd, Departments of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical
Center, Seoul, Korea
HONG J.P., LEE S.-W., SONG S.Y., AHN S.D., SHIN S.S., CHOI E.K. & KIM J.H. (2009) European Journal of
Cancer Care 18, 636–641
Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients
with head and neck malignancies
Mucositis of the oral cavity and pharynx is a major dose-limiting factor in the application of radiotherapy (RT)
to patients with head and neck cancer. Therefore, we evaluated the wound healing effect of human recombi-
nant epidermal growth factor (rhEGF) in head and neck cancer and lymphoma patients with irradiation (with
or without combined chemotherapy-induced oral mucositis). Patients at Asan Medical Center who had
undergone deﬁnitive RT of the head and neck region with or without combined chemotherapy and who had
developed severe oral mucositis (higher than the Radiation Therapy Oncology Group grade 3) were treated with
topical rhEGF twice daily for 7 days. The evaluation of response with regard to oral mucositis was performed
1 week later. Of the 11 treated patients, three had nasopharyngeal carcinoma, three had carcinoma of the
oropharynx, two had carcinoma of the oral cavity, one had carcinoma of the hypopharynx and two had
lymphoma of the head and neck. Six patients received RT only, and ﬁve patients received concurrent
chemoradiotherapy. All patients showed improvements in their oral mucositis after topical treatment with
rhEGF in that the Radiation Therapy Oncology Group grade was signiﬁcantly decreased (P = 0.0000). This
ﬁnding suggests that rhEGF is effective and safe for the treatment of radiation-induced mucositis. Further
studies are needed to determine the optimal dosage and fractionation schedule.
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Radiation treatment (RT) is the major therapeutic modal-
ity in the management of head and neck cancer patients,
and the combination of RT and chemotherapy has been
shown to have enhanced antitumor effects, which may
increase the organ preservation rate (The Department of
Veterans Affairs Laryngeal Cancer Study Group 1991;
Lefebvre et al. 1996; Vokes et al. 2000; Fung et al. 2005).
Although RT combined with chemotherapy may improve
the outcome of head and neck cancer treatment, RT com-
bined with chemotherapy, especially with concurrent
chemoradiation therapy (CCRT), has been shown to
increase the incidence of oral and pharyngeal mucositis,
which may restrict this treatment of head and neck cancer
(Al-Sarraf et al. 1998; Forastiere & Trotti 1999; Fung et al.
2005). Radiation-induced injury to the oral and pharyngeal
mucosa triggers a cascade of problems, which make it
difﬁcult to complete the planned course of RT (Alden
et al. 1996; Garden 2003). Although interruption of RT
results in wound healing, it also allows the tumour cells
to recover, with consequent negative impact on the thera-
peutic effect of RT (Parsons et al. 1980; Alden et al. 1996).
Severe oral or pharyngeal mucositis is very painful, limit-
ing oral intake and resulting in prolonged malnutrition,
which decreases the quality of life for these patients and,
in rare instances, results in death (Teo et al. 1996; Dische
et al. 1997; Carter et al. 1999; Cengiz et al. 1999; Trotti
2000).
Rapidly regenerating tissues are easily damaged by
radiation or chemotherapy, as dividing cells are sensitive
to genotoxic agents. The turnover time of oral mucosal
cells is 5 days in mice and humans, so these cells, suscep-
tible to treatment, induce injury (Dorr & Kummermehr
1991; Dorr et al. 1994, 1995, 2002; Garden 2003). While
CCRT results in improved local tumour control and sur-
vival relative to RT alone, it also results in more severe
mucosal damage (Al-Sarraf et al. 1998; Calais et al. 1999).
Currently, symptomatic treatment is usually used, as
there is no effective radiation-protective method or thera-
peutic therapy for radiation-induced mucositis. According
to the more than 100 studies reviewed by Plevova (Plevova
1999), there is no agent or method that is uniformly effec-
tive in preventing or treating the oral mucositis that
results from RT.
Epidermal growth factor (EGF), which was ﬁrst discov-
ered by Cohen in 1962 (Cohen 1962), is a single-chain
polypeptide of 53 amino acids (Savage et al. 1972; Gregory
1975; Gresik et al. 1979). It is present in various normal
tissues and body ﬂuids, including the skin, mucosa, tears,
cornea, saliva, milk, semen and ﬂuids secreted by the
duodenal glands (Heitz et al. 1978; Carpenter 1980;
Steidler & Reade 1980; Cohen 1983; Olsen et al. 1986;
Thesleff et al. 1988; Waterﬁeld 1989; Weaver et al. 1990;
Ino et al. 1993; Epstein et al. 1997). EGF plays an impor-
tant role in maintaining tissue homeostasis, as it regulates
epithelial cell proliferation, growth and migration. In addi-
tion, it has an effect on angiogenesis for the nutritional
support of tissues. Thus, EGF has a radical effect on
wound healing and tissue generation. Recombinant
human EGF (rhEGF) has been shown to enhance the
mucosal wound healing process (Noguchi et al. 1991; Pro-
caccino et al. 1994; Girdler et al. 1995), which suggests
that it may be effective in the treatment of radiation-
induced oral mucositis. Therefore, we evaluated the
wound healing effects of rhEGF in 11 patients with
radiation-induced oral mucositis.
METHODS AND MATERIALS
Between March 1999 and December 2001, patients treated
with RT to the head and neck area, with or without che-
motherapy, at the Asan Medical Center were recruited to
the study. The inclusion criteria were severe oral mucosi-
tis during RT. EGF (Easyef; DaeWoong Pharmaceuticals,
Seoul, Korea) was used in these patients. Patients who had
previous RT history in the head and neck region or
received other mucosal treatment were excluded in this
study. The highly puriﬁed rhEGF comprises 53 amino
acids and is biologically identical to human EGF. The
purpose of this pilot study was explained to all the
patients, who provided oral informed consent.
Epidermal growth factor was applied topically to the
oral cavity twice daily for 7 days. The dosage of rhEGF
was 25 mg/day. Changes in the extent and severity of oral
mucositis were evaluated at the 7 days later. Mucositis
evaluation was carried out with the unaided eye and was
restricted to the oral and soft palate. Oral mucositis was
scored according to the Radiation Therapy Oncology
Group (RTOG) criteria for acute morbidity of mucosal
membranes (Table 1). The spss for Windows ver. 12.0 soft-
ware was used for data analysis. The paired t-test with the
Table 1. Oral mucositis assessment scales of the RTOG
(Radiation Therapy Oncology Group)
Grade Acute mucositis
0 None
1 Erythema of the mucosa
2 Patchy reaction <1.5 cm, non-contiguous
3 Conﬂuent reaction >1.5 cm, contiguous
4 Necrosis or deep ulceration, bleeding
EGF treatment for oral mucositis
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63795% conﬁdence interval was used to compare the grades
of mucositis before and after EGF treatment.
RESULTS
Eleven patients, nine men and two women, with a median
age of 51 years (range 34–70 years), were recruited to the
present study. Of these 11 patients, three had nasopharyn-
geal carcinoma, three had carcinoma of the oropharynx,
two had carcinoma of the oral cavity, one had carcinoma
of the hypopharynx and two had lymphomas of the head
and neck. Five of the patients were treated with CCRT
(Table 2). All patients received the planned radiation dose.
None of the patients had to interrupt RT because of acute
mucositis.
Prior to EGF treatment, four patients had grade 4 and
seven patients had grade 3 radiation-induced oral mucosi-
tis; their RT doses ranged from 25.2 Gy to 58.2 Gy
(median, 32.0 Gy). Following topical treatment with EGF
spray for 1 week, all of the patients showed improvements
in oral mucositis, with signiﬁcantly decreased mean
RTOG grades (P = 0.0000). Of the four patients with grade
4 mucositis, two improved to grade 3 and two improved
to grade 2, whereas, of the seven patients with grade 3
mucositis, ﬁve improved to grade 2 and two improved to
grade 1 (Fig. 1). Figure 2 shows the results for a represen-
tative patient who developed RTOG grade 4 mucositis
while receiving an RT dose of 48.0 Gy; this patient
improved to grade 2 after 1 week of topical treatment
with EGF.
DISCUSSION
Acute mucositis is a serious complication of RT. Mucosi-
tis of the oral cavity and pharynx is a major dose-limiting
factor for RT in patients with head and neck cancer. The
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Figure 1. Improved RTOG grades for oral mucositis following
topical treatment of the oral mucosa with rhEGF. RTOG, Radia-
tion Therapy Oncology Group; rhEGF, human recombinant
epidermal growth factor.
Figure 2. Photograph showing a represen-
tative patient with improved oral mucosi-
tis. Left panel, RTOG grade 4 mucositis
prior to treatment with rhEGF; right
panel, improvement to RTOG grade 2
after 1 week of treatment with rhEGF.
RTOG, Radiation Therapy Oncology
Group; rhEGF, human recombinant epi-
dermal growth factor.
Table 2. Patients’ characteristics
Variables No of Patients (%)
Gender
Male 9 (73)
Female 2 (27)
Age
Period 34–70
Median 51
Diagnosis
Nasopharyngeal cancer 3 (27)
Oropharyngeal cancer 3 (27)
Hypopharyngeal cancer 1 (9)
Oral cavity cancer 2 (18)
Lymphoma 2 (18)
Radiation dose
Range 39.6–72.0 Gy
Median 68.0 Gy
Concurrent chemoradiotherapy
No 6 (55)
Yes 5 (45)
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638treatment of RT-induced oral mucositis remains a chal-
lenge despite several pharmacologic interventions. Inter-
ruption of RT because of mucositis prolongs the overall
treatment time, which in turn can have a negative impact
on local control and may decrease survival rates (Parsons
et al. 1980; Maciejewski et al. 1983; Withers et al. 1988;
Fowler & Lindstrom 1992; Dische et al. 1997). Therefore,
the interruption of RT directly correlates with the
outcome of RT. In the present study, we show that topical
treatment of the oral mucosa with EGF is effective in
patients with radiation-induced mucositis. High concen-
trated EGF spray to the damaged mucosa is a unique
compared previous study (Girdler et al. 1995). A previous
Phase I clinical trial of rhEGF for chemotherapy-induced
oral mucositis showed that diluted, low-concentration
rhEGF, given as a mouthwash three times daily, delayed
the initiation of mucositis and decreased its severity
(Girdler et al. 1995). In contrast, we sprayed a high con-
centration of rhEGF directly onto the oral mucosa.
The therapeutic effect of EGF on mucosal damage,
including damage to the gastrointestinal tract, has been
investigated. EGF has been found to have therapeutic and
protective effects against gastric ulcers and intestinal
mucositis (Miyazaki et al. 1998). As oral mucosa is similar
to intestinal mucosa, it seemed reasonable to expect that
EGF would exert some effects on oral mucosa. The
mucosa is easily damaged by RT or chemotherapy, as the
epithelial cells of the mucosa divide very rapidly. In addi-
tion, rhEGF has been shown to enhance the healing of
chronic diabetic foot ulcers (Hong et al. 2006), and we
have observed that rhEGF increases the proliferation of
human ﬁbroblasts (unpublished observations), which
suggest that EGF is effective in various types of wound
healing. Based on these biological properties, we tested the
topical application of EGF for mucositis induced by anti-
cancer therapy.
Epidermal growth factor stimulates proliferation of
various normal and cancer cells. If exogenous provided
rhEGF was to stimulate the proliferation of cancer cells, it
should not be used in cancer patients because the radio-
therapy indication is malignant disease. According to Xia
et al., EGF had no stimulatory effect on human gastric
cancer cell growth in vitro or in vivo (Xia et al. 2002). In
nude mice transplanted with human breast carcinoma,
it was shown that rhEGF inhibited the growth of EGF
receptor (EGFR)-positive MX-1 cells in a dose-dependent
manner, whereas no changes were observed in the growth
of cells of EGFR-negative MCF-7, Br-10 or T-61 after treat-
ment with rhEGF. We performed on similar experiment
on 25 cancer cell lines and EGF did not stimulate cancer
cell proliferation (unpublished data).
Patients with high concentrations of EGF in the saliva
have been observed to recover more rapidly from oral
mucositis than patients with low concentrations of EGF
in the saliva, which suggests that EGF is associated with
the healing process in the oral mucosa (Ino et al. 1993).
The EGF concentration in the saliva is decreased by RT,
while the incidence of oral ulcer is increased in patients
with low concentrations of EGF (Epstein et al. 1997). We
believe that topical treatment with EGF accelerates the
recovery from mucosal damage caused by RT, with or
without chemotherapy, in that EGF is an important
protein for mucosal wound healing and cell proliferation
is an important factor for the healing of the oral mucosa.
EGF is one of the factors involved in the complex process
of wound healing.
Several other growth factors, including keratinocyte
growth factor (KGF), ﬁbroblast growth factor and trans-
forming growth factor (TGF), are also involved in mucosal
wound healing (Wymenga et al. 1999; Booth et al. 2000;
Dorr et al. 2002; Spielberger et al. 2004). KGF (Palifermin)
has been shown to heal mucosal wounds in animal models
(Dorr et al. 2002) and in human studies, and it has been
approved by the US Food and Drug Administration (FDA)
as a wound healing agent. Furthermore, the effect of KGF
has been demonstrated in a prospective randomized phase
III study (Spielberger et al. 2004). TGF-B3 has been found
to reduce radiation-induced cell damage because of its
ability to induce G1 phase arrest both in animals (Booth
et al. 2000) and humans (Wymenga et al. 1999). Although
different growth factors have been tested as mucosal
wound healing agents, the therapeutic mechanism gener-
ally involves epithelial cell proliferation. EGF is a candi-
date agent for wound healing in patients treated with RT
or chemotherapy. KGF stimulates cell growth in some
cancer cell lines (Ning et al. 1998), whereas there is no
report of cell growth stimulation by exogenous EGF (Gill
& Lazar 1981; Barnes 1982; Imai et al. 1982; Kamata et al.
1986; Christen et al. 1990). We believe that this ﬁnding
supports the use of EGF in cancer patients. Granulocyte
macrophage colony-stimulating factor (GM-CSF) has been
found to stimulate the proliferation of hematologic stem
cells and keratinocytes, and keratinocyte proliferation can
stimulate the wound healing process (Kaplan et al. 1992).
GM-CSF has been shown to be effective in the treatment
of severe mucositis in patients who have undergone
bone marrow transplantation (Nemunaitis et al. 1995),
although it does not reduce radiation-induced mucositis,
according to the one prospective randomized study
(Makkonen et al. 2000).
In summary, the results of this pilot study show that
topical treatment with rhEGF has a therapeutic effect on
EGF treatment for oral mucositis
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639radiation-induced oral mucositis. Randomized, controlled
clinical trials are required to substantiate this effect. In
addition, determinations of the optimal dose, fraction-
ation schedule and application method for rhEGF require
additional studies with larger numbers of patients.
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